Anti-Diabetes Drugs - Switzerland

The Anti-Diabetes Drugs market in Switzerland is anticipated to achieve a revenue of US$530.00m in the year 2024.
It is projected that this revenue will experience an annual growth rate (CAGR 2024-2029) of 7.17%, leading to a market volume of US$749.10m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, reaching US$37.84bn in 2024.
Switzerland's anti-diabetes drug market is flourishing due to the country's high healthcare standards and emphasis on research and development.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Switzerland has been experiencing steady growth in recent years.

Customer preferences: Swiss consumers are increasingly health-conscious and are actively seeking out products to manage their health. This has led to an increased demand for anti-diabetes drugs as the prevalence of diabetes in Switzerland continues to rise. Consumers are also becoming more aware of the potential complications associated with diabetes, such as cardiovascular disease and kidney failure, and are seeking out drugs that can effectively manage their condition.

Trends in the market: One trend in the Swiss Anti-Diabetes Drugs market is the increasing use of combination therapies. Combination therapies involve the use of multiple drugs to manage diabetes, and are becoming more popular as they can be more effective than single drug therapies. Another trend in the market is the increasing use of newer drugs, such as GLP-1 receptor agonists and SGLT-2 inhibitors. These drugs have been shown to be effective in managing diabetes and have fewer side effects compared to older drugs.

Local special circumstances: Switzerland has a high rate of diabetes, with approximately 5% of the population affected by the disease. This has led to a high demand for anti-diabetes drugs in the country. The Swiss healthcare system is also well-developed, with a strong emphasis on preventative care. This has led to increased access to anti-diabetes drugs for Swiss consumers, as the government provides subsidies for these drugs.

Underlying macroeconomic factors: The Swiss economy has been growing steadily in recent years, with a strong emphasis on innovation and technology. This has led to increased investment in the healthcare sector, including the development of new anti-diabetes drugs. The aging population in Switzerland is also a factor driving growth in the Anti-Diabetes Drugs market, as older individuals are more likely to develop diabetes and require medication to manage their condition.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.